Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

October 6th 2021

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Plinabulin/Docetaxel Demonstrates Durable Antitumor Benefit in EGFR Wild-Type NSCLC

October 6th 2021

The addition of plinabulin to docetaxel demonstrated durable anticancer benefit in terms of overall survival when used in the second- or third-line treatment of patients with EGFR wild-type non–small cell lung cancer who had progressed on a prior platinum-based regimen.

Dr. Patel on the Role of CTLA-4 Inhibitors in NSCLC

October 5th 2021

Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.

Dr. Girard on Real-World PFS Data With Durvalumab in NSCLC

October 5th 2021

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for NTRK+ TKI-Pretreated Advanced Solid Tumors

October 5th 2021

The FDA has granted a breakthrough therapy designation to repotrectinib as a potential therapeutic option for patients with advanced solid tumors that harbor an NTRK gene fusion who have progressed after treatment with 1 or 2 prior TRK TKIs, with or without prior chemotherapy, and who have no satisfactory alternative options.

Amivantamab Plus Lazertinib Demonstrates Activity After Osimertinib and/or Chemo in EGFR-Mutant NSCLC

October 5th 2021

Amivantamab-vmjw in combination with lazertinib demonstrated significant clinical activity with durable responses in patients with EGFR-mutated non–small cell lung cancer who had progressed on osimertinib.

Dr. Thomas on Potential Biomarkers of Response to Berzosertib/Topotecan in SCLC

October 4th 2021

Anish Thomas, MD, discusses potential biomarkers of response to the combination of berzosertib plus topotecan in patients with relapsed, platinum-resistant small cell lung cancer.

FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

October 4th 2021

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.

Cemiplimab/Chemo Represents New Frontline Option for Advanced NSCLC Without Actionable Mutations

October 4th 2021

Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.

Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLC

October 4th 2021

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.

Dr. Spira on the Role of Frontline Brigatinib in ALK+ NSCLC

October 4th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Molecular Testing and Multidisciplinary Care Is A Necessity in Metastatic NSCLC

October 1st 2021

Although adjuvant targeted therapy options are reserved for patients with EGFR-mutated non–small cell lung cancer, molecular testing is a critical step in the treatment of all patients with metastatic disease, where multiple driver mutations are associated with FDA-approved therapeutics.

Uncommon EGFR Mutations Come Into Focus With Novel NSCLC Therapies

October 1st 2021

The understanding of EGFR signaling in non–small cell lung cancer continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations.

Rovalpituzumab Tesirine Falls Flat in Small Cell Lung Cancer

October 1st 2021

Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.

Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLC

September 30th 2021

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Taletrectinib Elicits Encouraging Responses in Crizotinib-Pretreated ROS1+ NSCLC

September 28th 2021

The investigational next-generation ROS1/NTRK inhibitor taletrectinib was found to elicit encouraging responses with an acceptable toxicity profile in patients with ROS1-positive non–small cell lung cancer, according to preliminary data from the phase 2 TRUST trial.

Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

September 27th 2021

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Reinmuth on the Rationale for Examining PROs With Tepotinib in METex14-Altered NSCLC

September 27th 2021

Niels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC

September 27th 2021

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III non–small cell lung cancer.

Optellum, Johnson & Johnson Launch Strategic Collaboration in Lung Cancer

September 26th 2021

Optellum and the Lung Cancer Initiative at Johnson & Johnson plan to use Optellum’s artificial intelligence-based decision support software in an effort to increase lung cancer survival rates via disease prevention and early intervention.